What is a stock summary page? Click here for an overview.
Business Description
Lytix Biopharma AS
ISIN : NO0010405780
Share Class Description:
OSL:LYTIX: Ordinary SharesDescription
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 49.54 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 4.13 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -29.3 | |||||
| 3-Year EBITDA Growth Rate | -6.3 | |||||
| 3-Year EPS without NRI Growth Rate | -6.3 | |||||
| 3-Year FCF Growth Rate | 1.1 | |||||
| 3-Year Book Growth Rate | -31.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.89 | |||||
| 9-Day RSI | 48.57 | |||||
| 14-Day RSI | 47.78 | |||||
| 3-1 Month Momentum % | -6.67 | |||||
| 6-1 Month Momentum % | -14.86 | |||||
| 12-1 Month Momentum % | -9.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.91 | |||||
| Quick Ratio | 3.91 | |||||
| Cash Ratio | 3.56 | |||||
| Days Sales Outstanding | 461.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.7 | |||||
| Shareholder Yield % | -47.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -861.27 | |||||
| Net Margin % | -846.65 | |||||
| FCF Margin % | -632.05 | |||||
| ROE % | -163.07 | |||||
| ROA % | -120.95 | |||||
| ROIC % | -553.55 | |||||
| 3-Year ROIIC % | -156.53 | |||||
| ROC (Joel Greenblatt) % | -2802.53 | |||||
| ROCE % | -160.86 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.62 | |||||
| PB Ratio | 3.16 | |||||
| Price-to-Tangible-Book | 3.16 | |||||
| EV-to-EBIT | -2.26 | |||||
| EV-to-EBITDA | -2.29 | |||||
| EV-to-Revenue | 19.27 | |||||
| EV-to-FCF | -3.03 | |||||
| Price-to-GF-Value | 1 | |||||
| Price-to-Net-Current-Asset-Value | 3.25 | |||||
| Price-to-Net-Cash | 3.7 | |||||
| Earnings Yield (Greenblatt) % | -44.33 | |||||
| FCF Yield % | -20.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lytix Biopharma AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 11.134 | ||
| EPS (TTM) (kr) | -1.932 | ||
| Beta | -0.56 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.26 | ||
| Volatility % | 75.12 | ||
| 14-Day RSI | 47.78 | ||
| 14-Day ATR (kr) | 0.288269 | ||
| 20-Day SMA (kr) | 5.0005 | ||
| 12-1 Month Momentum % | -9.35 | ||
| 52-Week Range (kr) | 4.55 - 15 | ||
| Shares Outstanding (Mil) | 68.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lytix Biopharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lytix Biopharma AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lytix Biopharma AS Frequently Asked Questions
What is Lytix Biopharma AS(OSL:LYTIX)'s stock price today?
The current price of OSL:LYTIX is kr5.00. The 52 week high of OSL:LYTIX is kr15.00 and 52 week low is kr4.55.
When is next earnings date of Lytix Biopharma AS(OSL:LYTIX)?
The next earnings date of Lytix Biopharma AS(OSL:LYTIX) is 2025-05-15.
Does Lytix Biopharma AS(OSL:LYTIX) pay dividends? If so, how much?
Lytix Biopharma AS(OSL:LYTIX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers